EVAX (Evaxion Biotech AS) Interest Coverage : 0 (At Loss) (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Evaxion Biotech AS's Operating Income for the three months ended in Dec. 2024 was $-4.02 Mil. Evaxion Biotech AS's Interest Expense for the three months ended in Dec. 2024 was $1.70 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Evaxion Biotech AS's Interest Coverage or its related term are showing as below:

EVAX's Interest Coverage is not ranked ^*
in the Biotechnology industry.
Industry Median: 101.38
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Evaxion Biotech AS Interest Coverage Historical Data

The historical data trend for Evaxion Biotech AS's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Evaxion Biotech AS Interest Coverage Chart

Evaxion Biotech AS Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Coverage

Get a 7-Day Free Trial

Evaxion Biotech AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Coverage	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Evaxion Biotech AS's Interest Coverage

For the Biotechnology subindustry, Evaxion Biotech AS's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evaxion Biotech AS's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion Biotech AS's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Evaxion Biotech AS's Interest Coverage falls into.

Save Embed

;

Save Embed

;

Evaxion Biotech AS Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Evaxion Biotech AS's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Evaxion Biotech AS's Interest Expense was $-0.96 Mil. Its Operating Income was $-14.73 Mil. And its Long-Term Debt & Capital Lease Obligation was $9.63 Mil.

Evaxion Biotech AS did not have earnings to cover the interest expense.

Evaxion Biotech AS's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the three months ended in Dec. 2024, Evaxion Biotech AS's Interest Expense was $1.70 Mil. Its Operating Income was $-4.02 Mil. And its Long-Term Debt & Capital Lease Obligation was $9.63 Mil.

The higher the ratio, the stronger the company's Financial Strength is.

Evaxion Biotech AS (NAS:EVAX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Evaxion Biotech AS Interest Coverage Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

Evaxion Biotech AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

Dr. Neergaards Vej 5f, Hoersholm, DNK, 2970

Website

https://www.evaxion.ai

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are: EVX-01, EVX-03, and EVX-02, which are vaccine candidates being developed for the treatment of various solid cancers. In addition, the company is developing EVX-B1, EVX-B2, EVX-B3, EVX-V1, and multiple other vaccine candidates for various infectious diseases, such as cytomegalovirus, N.gonorrhoeae, bacterial pathogens, and others.